Ironwood Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas A. McCourt
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 100 Summer Street Boston MA United States of America 02110
- IPO Date
- Feb 3, 2010
- CIK
- 0001446847
- Website
- ironwoodpharma.com
- Similar Companies
- Business
- Ironwood Pharmaceuticals, Inc. is a biotechnology company primarily engaged in the development, commercialization, and manufacture of gastrointestinal (GI) and other related therapeutics. Its main products and services include the development and marketing of linaclotide, marketed under the brand name LINZESS, for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC); the development of additional GI-related therapies; and research and development efforts for pipeline candidates targeting various GI disorders and cardiovascular and metabolic conditions. The company provides pharmaceutical products primarily in the United States and has engaged in partnerships and collaborations to expand its drug portfolio and pipeline. Ironwood Pharmaceuticals was founded in 1998 and is headquartered in Cambridge, Massachusetts. In the last one to two years, Ironwood Pharmaceuticals has focused on extending its commercial portfolio through strategic partnerships and new product launches to broaden its therapeutic offerings. The company has also pursued clinical development for pipeline candidates aimed at expanding its footprint in gastrointestinal and metabolic diseases. Recent operational changes include initiatives to enhance marketing efforts for its lead product, LINZESS, and efforts to expand patient access and market share in the U.S. Additionally, Ironwood has been involved in collaborations to co-develop and commercialize new therapies, reinforcing its strategic shift toward growth via innovation and partnerships, although exact recent acquisition or funding details are not explicitly available as of the latest reports. The company operates primarily in the biotechnology industry sector, targeting healthcare providers and patients with specialized pharmaceutical needs. This comprehensive profile reflects Ironwood Pharmaceuticals’ core focus on innovative GI therapeutic solutions and ongoing strategic moves to fortify its market position and pipeline development. The company continues to operate with a strong presence in North America, leveraging its established product LINZESS while expanding through research collaborations and potential new product introductions.
Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Best 5 Small-Cap Stocks With Forward EPS Growth Above 125%